Kornimate/medical-research-clean huggingface dataset:
colorado oral strengthening device

Conditions: Parkinson Disease

Summary: university of colorado is looking for adults with parkinson's disease to participate in a research study. the study aims to explore how a novel low technology device can achieve an increase in tongue strength comparable to standard of care exercise using tongue depressors but with the kinematics and simple biofeedback of existing high cost devices. research has shown that tongue resistance exercises paired with biofeedback have resulted in improved tongue strength to support chewing, control of food and liquid in the mouth, and propulsion of material for a swallow.

when an individual contacts the pi or the department research coordinator, a preliminary screen will be administered for any obvious exclusion. if there are no exclusions, the first visit will be scheduled. at this initial visit, a full description of the study and exercise protocol will be provided. a health history questionnaire and an eat-10 questionnaire will be administered. if consent is obtained, baseline tongue strength will be measured using the iopi device. individuals with parkinson's will be randomized to exercise with the cosd or with the tongue depressors. those who will use the cosd will be start with no less than 60% max strength and receive an exercise log. those using the tongue depressors will also receive an exercise log. all participants will receive a full demonstration of the exercise and will be asked to return the demonstration. the second visit will be scheduled for all participants the following week. at that time, the eat-10 and tongue strength will be re-assessed. the exercise logs will be reviewed to ensure compliance. participants using the cosd will be issued a new device that is no less than 80% of their max strength. the third visit will be scheduled the following week (week 3). the eat-10 questionnaire and tongue strength will be reassessed. the exercise log will be reviewed for compliance. cosd will be inspected for any signs of wear and a new one will be issued if the device appears worn. the last 2 visits will be scheduled during weeks 6 and 8 of the exercise protocol. the eat-10 and tongue strength will be re-assessed, and the exercise log will be reviewed for compliance. the cosd will be inspected for any signs of wear and a new one will be issued if the device appears worn. in addition, during the final visit, all participants will be asked to complete a questionnaire regarding their satisfaction with the exercise device they were assigned. the cosd will be collected at that visit.

Eligibility criteria:
inclusion criteria: 1. 18 to 89 years old(inclusive) 2. diagnosis of parkinson's disease 3. hoen and yahr stage ii-iv 4. signs or symptoms of dysphagia evidenced by an eat-10 score of 3 or more exclusion criteria: 1. unwilling to sign the informed consent 2. atypical parkinson's disease, parkinson plus, lewy body dementia, multiple system atrophy 3. history of head or neck cancer 4. history of seizures 5. current or past disorders of the jaw 6. allergy to device materials

Keywords: tongue strength novel exercise
brief alcohol intervention for school-to-work transitions

Conditions: Binge Drinking

Summary: this is a 2-year research project to test the efficacy of brief motivational intervention for reducing heavy alcohol use in young adults transitioning out of high school. participation occurs within 3 months prior to graduation or within 1 year following graduation or dropout from high school. heavy drinkers ages 17-20 will be randomly assigned to receive one session of bmi or one session of relaxation training. all participants complete identical assessments at baseline and immediately post-intervention (during session 1). participants also complete in-person 6-week and 3-month follow up assessments to evaluate intervention effects. study aims involve: a) testing the comparative efficacy of bmi; b) identifying moderators (person-level predictors) of intervention response; and c) identifying mediators (mechanisms) of intervention effects, that is, how bmi exerts its effect on outcomes.

this study tested the efficacy of a single session of bmi for reducing heavy drinking and related adverse consequences among underage young adult drinkers not attending a 4-year college or university. we designed the intervention to be delivered proximal to the transition out of high school (with or without graduation), because such periods of transition and discontinuity in the life course present opportunities to positively alter developmental paths (masten et al., 2009). thus, interventions timed to co-occur with naturalistic transition points may have great potential for decreasing drinking trajectories or preventing harmful escalations in trajectories going forward. to increase the applicability of our findings to the heterogeneous population of community-dwelling young adults, our recruitment targeted a purposefully inclusive "non-4-year-college" population. we hypothesized that, compared to a time and attention-matched control condition (i.e., relaxation training \[rel\]), bmi would result in significantly reduced heavy drinking and reduced adverse consequences of alcohol use at 6-week and 3-month follow-up.

Eligibility criteria:
inclusion criteria: * high school students anticipating graduation within 3 months, drop outs or graduates * males must report at least one day drinking 5 or more standard drinks in past month * females must report at least one day drinking 4 or more standard drinks in past month exclusion criteria: * plans to enroll at traditional 4-year college within 12 months * plans to enter military within next 12 months * plans to move more than 1 hour from current location in within 12 months
platelet activation and reactivity in acute exacerbations of copd

Conditions: COPD Exacerbation

Summary: chronic obstructive pulmonary disease (copd) is known for development of severe cardiovascular co-morbidities. systemic inflammation during acute exacerbations of copd (ae-copd) is thought to play a role in development of cardiovascular disease. platelets contribute to acute cardiovascular events and atherosclerosis. when platelets are activated, they form complexes with monocytes. these platelet-monocyte complexes (pmcs) are an early process in atherothrombosis and promote inflammation. in copd, platelet function in ae-copd is scarcely studied. this study aims to address this gap by investigating platelet function and coagulation in patients with ae-copd and after convalescence.


Eligibility criteria:
inclusion criteria: * \>40 years * spirometry confirmed diagnosis of copd (i.e. post-bronchodilator fev1/fvc \< 70% and less than 12% on reversibility testing\< lower limit of normal (lln)) * ≥10 pack years of smoking exclusion criteria: * use of anti-coagulation or other platelet function inhibitors * asthma * chronic inflammatory diseases, for example rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (sle) * malignancies

Keywords: copd cardiovascular disease platelets inflammation
safety and efficacy of cd123-targeted car-t therapy for relapsed/refractory acute myeloid leukemia

Conditions: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute

Summary: this is a single arm study to evaluate the efficacy and safety of cd123-targeted car-t cells therapy for patients with relapsed/refractory acute myeloid leukemia.

there are limited options for treatment of relapse/refractory acute myeloid leukemia. cd123 is expressed on most myeloid leukemia cells so it is an ideal target for car-t. some researches have revealed that cd123 is a marker of leukemia stem cells, which indicates that the eradication of cd123 cells may prevent relapse of leukemia. in this study, investigators will evaluate the safety and efficacy of car-t targeting cd123 in patients with relapsed/refractory acute myeloid leukemia. the primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent; 2. diagnose as relapsed /refractory acute myeloid leukemia, and meet one of the following conditions: 1. failed to standard chemotherapy regimens; 2. relapse after complete remission, high-risk and / or refractory patients ; 3. relapse after hematopoietic stem cell transplantation; 3. evidence for cell membrane cd123 expression; 4. all genders, ages: 3 to 75 years； 5. the expect time of survive is above 12 weeks; 6. kps\>60； 7. no serious mental disorders ; 8. left ventricular ejection fraction ≥50% 9. sufficient hepatic function defined by alt/ast≤3 x uln and bilirubin≤2 x uln; 10. sufficient renal function defined by creatinine clearance≤2 x uln; 11. sufficient pulmonary function defined by indoor oxygen saturation≥92%; 12. with single or venous blood collection standards, and no other cell collection contraindications; 13. ability and willingness to adhere to the study visit schedule and all protocol requirements. exclusion criteria: 1. have received car-t therapy or other genetically modified cell therapy before screening； 2. participated in other clinical research within 1 month before screening； 3. have received the following anti-tumor treatment before screening: have received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except those who have confirmed disease progression after treatment; 4. live attenuated vaccine within 4 weeks before screening; 5. convulsion or stoke within past 6 months; 6. previous history of other malignancy; 7. presence of uncontrolled active infection; 8. subjects with positive hbsag or hbcab positive and peripheral blood hbv dna titer is higher than the lower limit of detection of the research institution; hcv antibody positive and peripheral blood hcv rna titer is higher than the lower limit of detection of the research institution; hiv antibody positive; syphilis primary screening antibody positive; 9. pregnant or breasting-feeding women; 10. any situation that investigators regard not suitable for attending in this study or may affect the data analysis.

Keywords: leukemia acute myeloid leukemia cd123 car-t
sperm micro-swim up technique; process and select in the same dish: a sibling-oocyte-split design

Conditions: Assisted Reproductive Technology; Infertility

Summary: a sibling-oocyte-split design will be conducted on oocytes before denudation and divided into two groups : control group (mii oocytes will be injected using sperm processed by density gradient method) and sample group ( mii oocytes will be injected by sperm processed using micro-swim up technique)

in this study investigators compare a novel sperm processing and selection method which is (fast, cheap and safe) with the well known processing method of sperm "density gradient (dg)" the dishes will be prepared with droplets of handling medium for oocytes (droplet volume 10 μl), and an h pattern using pvp will be produced, finally, all the droplets will be overlaid with mineral oil. control group : oocytes will be injected using sperm after processing with dg and will be selected from control pvp microdroplets sample group: sperm will be directly loaded in specific icsi dishes where is the pvp microdroplets is prepared on "h" pattern and will be selected from the far point from the deposition point and will be injected into the oocytes from the sample group all injected mii oocytes from both groups will then be cultured, with each group demarcated in separate place in the culture dish then according to the randomisation embryo transfer will be selected from one of both groups then the quality of the embryos will be reported and the pregnancy rate

Eligibility criteria:
inclusion criteria: * the normal \& high responders were selected according to : * age: 18 - 40 years * anti-müllerian hormone (amh): \> 1.0 ng/ml * number of aspirated oocytes:more than or equal 8 * bmi \< 34 exclusion criteria: * age \> 40 years; * amh \< 1.0 ng/ml; * aspirated oocytes \< 8. * severe male factor * testicular aspirated sperm

Keywords: sperm micro-swim up icsi semen processing density gradient
protocol for comparing the efficacy of three reconstruction methods of the digestive tract after proximal gastrectomy

Conditions: Proximal Gastric Adenocarcinoma; Gastrectomy; Anastomosis; Reflux Esophagitis; Postoperative Complications

Summary: the efficacy of three different reconstruction methods after proximal gastrectomy will be investigated in this study through a prospective, multicenter, randomized controlled trial.

in the trial, 180 patients with proximal early gastric cancer will be enrolled and then randomly assigned to one of three groups: group a (kamikawa, n = 60), group b (single-tract jejunal interposition, n = 60), or group c (sofy reconstruction, n = 60). the general information, past medical history, laboratory and imaging findings, and surgical procedures of each patient will be recorded. patients in group a, group b and group c will receive kamikaze reconstruction, single-tract jejunal interposition reconstruction and sofy reconstruction respectively after standard proximal gastrectomy and lymph nodes dissection. the primary endpoint will be the incidence of reflux esophagitis, while the incidence of anastomotic leakage, anastomotic stenosis, operative time, and intraoperative blood loss will be secondary endpoints to compare the efficacy of these three reconstruction methods after proximal gastrectomy.

Eligibility criteria:
inclusion criteria: * age between 20-75 years old, male or female; * pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： ia and ib (t1n0m0, t1n1m0, and t2n0m0) (14) according to the eighth edition of the ajcc (15); * no distant metastasis observed on preoperative chest radiograph, abdominal ultrasound or upper abdominal ct; * asa grade 1-3; * patients without contraindications to surgery; * patients and their families voluntarily signing the informed consent form and participating in the study; exclusion criteria: * patients diagnosed with primary tumors or distant metastasis; * patients whose tumor is located in the greater curvature side of the stomach; * patients with coagulation dysfunction which could not be corrected; * patients who were diagnosed with viral hepatitis and cirrhosis; * patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin; * patients with organ failure such as heart, lung, liver, brain, kidney failure; * patients with ascites or cachexia preoperatively in poor general conditions; * patients diagnosed with immunodeficiency, immunosuppression or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, sle, etc.). * patients refusing to sign the informed consent of the study;
a retrospective, multicenter, controlled clinical trail: to evaluate the efficiency and safety of intracranial aneurysm assistive software in the preoperative assessment

Conditions: Intracranial Aneurysm

Summary: the goal of this clinical trail is to evaluate the efficiency and safety of intracranial aneurysm assistive software in the preoperative assessment. the trail is designed as retrospective, multicenter, controlled clinical trail. collecting probable cases images retrospectively according to inclusion criteria and exclusion criteria strictly. controlling bias strictly, to make sure the efficiency and safety of intracranial aneurysm assistive software is evaluated reliably and precisely. in our trail, software-assisstant planning controls against experienced-surgeon-independent planning，which aims to avoid bias effictively and eliminate non-test interferences.


Eligibility criteria:
inclusion criteria: 1. aged 18-80y, no gender limitation. 2. non-ruptured intracranial saccular aneurysm with specific intracranial cta images; target aneurysm has performed intravascular coiling treatment. 3. intracranial aneurysm diameter range from 3mm to 10mm. 4. the shape of aneurysm is regular without daughter sac or more than 2 lobulations. inclusion criteria of images: 1. the number of detector rows of computed tomography(ct) is more than 16 rows. 2. slice thickness ≤ 0.625mm, whole-brain image is considered. 3. both plain scan sequences and enhancer sequence are required. exclusion criteria: 1. combined with cerebral hemorrhage; 2. combined with cerevascular malformation or cerebral occupying lesion; 3. fusiform aneurysm or dissection aneurysm; 4. significant proximal stenosis of parent artery; 5. intracaverous internal carotid artery aneurysm; 6. target aneurysm has been performed flow-diverter stents treatment. exclusion criteria of images: 1. none dicom format; 2. quality score less than 3 scores; 3. metal artifacts existance.

Keywords: intracranial aneurysm intravascular coiling embolization
effect of local intraoperative steroid on dysphagia after acdf

Conditions: Dysphagia

Summary: the purpose of this study is to determine if the incidence and duration of postoperative dysphagia are improved in the participants receiving a local injection of methylprednisolone with systemic dexamethasone when compared to those receiving the usual systemic dexamethasone.

postoperative dysphagia is a known complication of anterior cervical spinal fusion (acf) surgery with a published incidence that ranges from 1.7% to 50.3%.1-9 the pathophysiology of post-operative dysphagia is not fully understood and is subject to further study. postoperative dysphagia has been reported to improve with time with a mean incidence of 19.8% at 6 months, 16.8% at 12 months, and 12.9% at 24 months after acdf. the investigator's standard of practice is to provide 10mg of dexamethasone iv intraoperatively in order to reduce postoperative prevertebral soft tissue swelling. despite the growing popularity of acdf procedures, there is a lack of clear evidence supporting the utilization of perioperative corticosteroids in the setting of an acdf.

Eligibility criteria:
inclusion criteria: * patients undergoing a primary 1- to 3-level acdf: (a) diagnosis: myelopathy, radiculopathy, myeloradiculopathy, stenosis, herniated nucleus pulposus, degenerative disc disease, spondylosis, osteophytic complexes, and foraminal stenosis * patients able to provide informed consent exclusion criteria: * allergies or other contraindications to medicines in the protocol including: (a) existing history gastrointestinal bleeding * existing history of dysphagia * current smokers * cervical spine trauma

Keywords: anterior cervical discectomy and fusion prevertebral swelling swallowing methylprednisolone intraoperative steroid
comparison of elution swab (eswab) and amies transport swabs for screening patients for methicillin resistant staphylococcus aureus (mrsa) and vancomycin resistant enterococci (vre) colonization

Conditions: Eluted Swab

Summary: 1.to assess whether the elution swab (eswab) is superior to amies transport swabs for the detection of methicillin resistant staphylococcus aureus (mrsa) and vancomycin resistant enterococci (vre) in colonized patients and to determine whether nasal cultures alone is sufficient for detection of mrsa isolates in hospitalized patients. 2.to assess patient comfort in the use of the eswab vs. amies transport swab for screening patients for methicillin resistant staphylococcus aureus and vancomycin-resistant enterococcus.

mrsa is a major cause of nosocomial and life threatening infections. infections with mrsa have been associated with a significantly higher morbidity, mortality and costs than methicillin-susceptible s. aureus (mssa).1 selection of these organisms has been greatest in the healthcare setting; however, mrsa have also become more prevalent in the community.2 to control the transmission of mrsa, the society for healthcare epidemiology of america (shea) has recommended guidelines, which include an active surveillance program to identify potential reservoirs and a rigorous infection control program to control the spread of mrsa. accurate identification of patients colonized with mrsa is essential in managing the transmission of the organism. it is currently unknown whether the currently utilized collection rayon swab is the optimal swab in detecting colonized patients the purpose of this study is to directly compare whether eluted (eswab) swab is superior to the currently utilized rayon swab in identifying mrsa/vre colonized patients.

Eligibility criteria:
inclusion criteria: * hospitallized patients known to be colonized with mrsa/vre exclusion criteria: * unable to provide informed consent

Keywords: mrsa, vre
assessment of a procedure for managing oral anticoagulants (naco) in the management of fractures

Conditions: Femur Fracture

Summary: the purpose of this study is to demonstrate that by allowing patients with an anticoagulant level less than 100 ng/ml to have their fracture managed surgically, will reduce the delay in surgery and therefore the complications associated. it will also demonstrate that there are no more complications with this new management than from remaining with a bleeding fracture.

fracture of the upper extremity of the femur are constantly on the increase and represent a public health issue in a population with increasing life expectancy. in the majority of cases, this fracture requires rapid surgical treatment, ideally within 48 hours, before complications, associated with the supine position, appear. a prolonged surgical delay is responsible for multiple complications and increase mortality in a potentially comorbid and fragile population. oral anticoagulants (nacos) are now widely used in general population for cardiovascular diseases, such as non-valvular atrial fibrillation or thrombo-embolic events. their activity and circulation rate are assessed by an anti-xa assay. the current recommendation for scheduled surgery is an assay with an anti-xa activity of less than 50 ng/ml. the acquisition of this assay and the wait for a decrease in anti-xa activity are currently a factor of lengthening the surgical delay leading to proposal a new dosage. by offering the possibility of surgical management with an anti-xa activity of less than 100 ng/ml, the purpose is to demonstrate a reduction in surgical delay (less than 48 hours) and associated complications. one of the secondary purposes is also to demonstrate that there are no more intra and post-operative complications with this new protocol.

Eligibility criteria:
inclusion criteria : * patients on naco undergoing surgery for fracture of the upper end of the femur, * 18 years and over, * informed patients who did not object. exclusion criteria : * patients under court protection, * patients under guardianship/curators .

Keywords: naco fracture upper end of the femur department new procedure